Dicerna Pharmaceuticals Secures $4,000,000 Series B Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=3be9be83-0ffd-41d9-8912-69b03ef3446d&Preview=1 - Date
10/22/2010 - Company Name
Dicerna Pharmaceuticals - Mailing Address
480 Arsenal Street Building 1 Watertown, MA 02472 - Company Description
Dicerna Pharmaceuticals is a venture-backed startup developing novel therapeutics in multiple therapeutic areas based on Dicer substrate technology, which makes use of the RNA interference mechanism. - Website
http://www.dicerna.com - Transaction Type
Venture Equity - Transaction Amount
$4,000,000 - Transaction Round
Series B - Proceeds Purposes
Proceeds from the Series B financing will be used to advance Dicerna’s lead in-house program in oncology towards clinical development and progress its other preclinical programs. The company also plans to use the proceeds to continue to develop its delivery technologies, including its proprietary lipid nanoparticle system and novel lipid platform, and targeted delivery systems which combine Dicerna’s DsiRNA molecules with targeting moieties such as peptides, aptamers or antibodies. - M&A Terms
- Venture Investor
SR One
